KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Enterprise Value (2017 - 2025)

Bionano Genomics' Enterprise Value history spans 7 years, with the latest figure at -$13.3 million for Q3 2025.

  • For Q3 2025, Enterprise Value fell 11.52% year-over-year to -$13.3 million; the TTM value through Sep 2025 reached -$13.3 million, down 11.52%, while the annual FY2024 figure was -$9.5 million, 85.81% up from the prior year.
  • Enterprise Value for Q3 2025 was -$13.3 million at Bionano Genomics, up from -$14.6 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$9.5 million in Q4 2024 and bottomed at -$362.1 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$77.1 million (2023), against an average of -$125.2 million.
  • The largest annual shift saw Enterprise Value plummeted 4345.69% in 2021 before it skyrocketed 86.47% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$250.6 million in 2021, then soared by 54.84% to -$113.2 million in 2022, then skyrocketed by 41.01% to -$66.8 million in 2023, then soared by 85.81% to -$9.5 million in 2024, then crashed by 40.7% to -$13.3 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Enterprise Value are -$13.3 million (Q3 2025), -$14.6 million (Q2 2025), and -$18.2 million (Q1 2025).